These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 33914918)

  • 1. An international comparison of anti-SARS-COV-2 assays used for seroprevalence surveys from blood component providers.
    Lewin A; Drews SJ; Lieshout-Krikke R; Erikstrup C; Saeed S; Fady H; Uzicanin S; Custer B; O'Brien SF;
    Vox Sang; 2021 Oct; 116(9):946-954. PubMed ID: 33914918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence: Navigating the absence of a gold standard.
    Saeed S; O'Brien SF; Abe K; Yi QL; Rathod B; Wang J; Fazel-Zarandi M; Tuite A; Fisman D; Wood H; Colwill K; Gingras AC; Drews SJ
    PLoS One; 2021; 16(9):e0257743. PubMed ID: 34555095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of Commercial SARS-CoV-2 Immunoassays in a Nigerian Population.
    Ige F; Hamada Y; Steinhardt L; Iriemenam NC; Uwandu M; Greby SM; Aniedobe M; Salako BL; Rangaka MX; Abubakar I; Audu R
    Microbiol Spectr; 2021 Oct; 9(2):e0068021. PubMed ID: 34612691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role and diagnostic accuracy of serology for COVID-19.
    Kundu D; Gautam P; Dayanand D; Gunasekaran K; Manesh A; Sebastian M; Abhilash KPP; Zachariah A; George T; Sathyendra S; Hansdak SG; Abraham OC; Iyadurai R; Thangakunam B; Gupta R; Karthik R; Moorthy M; Varghese GM
    BMC Infect Dis; 2022 Apr; 22(1):390. PubMed ID: 35439957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of six commercially available SARS-CoV-2 antibody assays-Choice of assay depends on intended use.
    Nilsson AC; Holm DK; Justesen US; Gorm-Jensen T; Andersen NS; Øvrehus A; Johansen IS; Michelsen J; Sprogøe U; Lillevang ST
    Int J Infect Dis; 2021 Feb; 103():381-388. PubMed ID: 33310021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Evaluation of the Diagnostic Performance of Different Principles of SARS-CoV-2 Commercial Antibody Tests in COVID-19 Patients].
    Dinç HÖ; Özdemir YE; Alkan S; Güngördü Dalar Z; Gareayaghi N; Sirekbasan S; Tuyji Tok Y; Kuşkucu MA; Karaali R; Özbey D; Aygün G; Midilli K; Kocazeybek B
    Mikrobiyol Bul; 2021 Apr; 55(2):207-222. PubMed ID: 33882652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Seroprevalence of SARS-CoV-2 Antibodies in Africa: A Systematic Review and Meta-Analysis.
    Hajissa K; Islam MA; Hassan SA; Zaidah AR; Ismail N; Mohamed Z
    Int J Environ Res Public Health; 2022 Jun; 19(12):. PubMed ID: 35742506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of initial SARS-CoV-2 seroprevalence in the most affected districts in the municipality of São Paulo, Brazil.
    Tess BH; Granato CFH; Alves MCGP; Pintão MCT; Nunes MC; Rizzatti EG; Reinach FC
    Braz J Infect Dis; 2021; 25(4):101604. PubMed ID: 34416142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Performance Comparison of Five SARS-CoV-2 Antibody Assays for Seroprevalence Studies.
    Park Y; Hong KH; Lee SK; Hyun J; Oh EJ; Lee J; Lee H; Song SH; Kee SJ; Kwon GC; Kim SH; Do HN; Kim AR; Lee JW; Kim SS; Kim HS
    Ann Lab Med; 2022 Jan; 42(1):71-78. PubMed ID: 34374351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surveillance of SARS-CoV-2 antibodies of patients in the local affected area during Wuhan lockdown.
    Tang Y; Sun J; Yuan Y; Yao F; Zheng B; Yang G; Xie W; Ye G; Li Z; Jiao X; Li Y
    BMC Infect Dis; 2022 Jan; 22(1):10. PubMed ID: 34983429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SARS-CoV-2 antibody seroprevalence in Lebanon: findings from the first nationwide serosurvey.
    Hoballah A; El Haidari R; Siblany G; Abdel Sater F; Mansour S; Hassan H; Abou-Abbas L
    BMC Infect Dis; 2022 Jan; 22(1):42. PubMed ID: 35012464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Seroprevalence of anti-SARS-CoV-2 IgG/IgM antibodies in Borgosesia (Piedmont Region, Northern Italy) population: a surveillance strategy in post-lockdown period?].
    Alessi D; Borré S; Barale A; Isabella A; Milano F; Rossi MA; Silano V; Piu N; Cena T; Faggiano F;
    Epidemiol Prev; 2020; 44(5-6 Suppl 2):200-206. PubMed ID: 33412811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Limited specificity of commercially available SARS-CoV-2 IgG ELISAs in serum samples of African origin.
    Emmerich P; Murawski C; Ehmen C; von Possel R; Pekarek N; Oestereich L; Duraffour S; Pahlmann M; Struck N; Eibach D; Krumkamp R; Amuasi J; Maiga-Ascofaré O; Rakotozandrindrainy R; Asogun D; Ighodalo Y; Kann S; May J; Tannich E; Deschermeier C
    Trop Med Int Health; 2021 Jun; 26(6):621-631. PubMed ID: 33666297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Seroprevalence of SARS-CoV-2-specific IgG antibodies in Kashmir, India, 7 months after the first reported local COVID-19 case: results of a population-based seroprevalence survey from October to November 2020.
    Khan SMS; Qurieshi MA; Haq I; Majid S; Ahmad J; Ayub T; Bhat AA; Fazili AB; Ganai AM; Jan Y; Kaul RU; Khan ZA; Masoodi MA; Mushtaq B; Nazir F; Nazir M; Raja MW; Rasool M; Asma A; Ayoub S; Aziz M; Bhat AA; Chowdri IN; Ismail S; Kawoosa MF; Khan MA; Khan MS; Kousar R; Lone AA; Nabi S; Obaid M; Qazi TB; Sabah I; Sumji IA
    BMJ Open; 2021 Sep; 11(9):e053791. PubMed ID: 34556519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Seroprevalence of SARS-CoV-2 among Blood Donors and Changes after Introduction of Public Health and Social Measures, London, UK.
    Amirthalingam G; Whitaker H; Brooks T; Brown K; Hoschler K; Linley E; Borrow R; Brown C; Watkins N; Roberts DJ; Solomon D; Gower CM; de Waroux OLP; Andrews NJ; Ramsay ME
    Emerg Infect Dis; 2021 Jul; 27(7):1795-1801. PubMed ID: 34152947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the performance of SARS--CoV--2 antibody assays for a longitudinal population-based study of COVID--19 spread in St. Petersburg, Russia.
    Barchuk A; Shirokov D; Sergeeva M; Tursun Zade R; Dudkina O; Tychkova V; Barabanova L; Skougarevskiy D; Danilenko D
    J Med Virol; 2021 Oct; 93(10):5846-5852. PubMed ID: 34081328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Seroprevalence of SARS-CoV-2 Assessed by Four Chemiluminescence Immunoassays and One Immunocromatography Test for SARS-Cov-2.
    Cerino P; Gallo A; Pierri B; Buonerba C; Di Concilio D; Cuomo MC; Vassallo L; Lo Conte G; Coppola A; Pizzolante A; Boccia G; Ferrucci V; Atripaldi L; Triassi M; Pacella D; Cennamo M; Romano P; Sorbo TM; Furno A; Catapano O; Contina A; Perruolo G; D'Amora M; Terracciano D; Portella G
    Front Public Health; 2021; 9():649781. PubMed ID: 33996728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changing Patterns of SARS-CoV-2 Seroprevalence among Canadian Blood Donors during the Vaccine Era.
    Reedman CN; Drews SJ; Yi QL; Pambrun C; O'Brien SF
    Microbiol Spectr; 2022 Apr; 10(2):e0033922. PubMed ID: 35412385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of xMAP SARS-CoV-2 Multi-Antigen IgG assay in Nigeria.
    Iriemenam NC; Ige FA; Greby SM; Mpamugo A; Abubakar AG; Dawurung AB; Esiekpe MK; Thomas AN; Okoli MU; Awala SS; Ugboaja BN; Achugbu CC; Odoh I; Nwatu FD; Olaleye T; Akayi L; Akinmulero OO; Dattijo J; Onokevbagbe E; Okunoye O; Mba N; Agala NP; Uwandu M; Aniedobe M; Stafford KA; Abimiku A; Hamada Y; Swaminathan M; Okoye MI; Steinhardt LC; Audu R
    PLoS One; 2022; 17(4):e0266184. PubMed ID: 35363818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of robust, indigenous ELISA for detection of IgG antibodies against CoV-2 N and S proteins: mass screening.
    Srivastava AK; Gupta A; Chauhan D; Meena RC; Sugadev R; Eslavath MR; Gupta H; Karuna ; Singh S; Singh Y; Tiwari RP; Kohli V; Varshney R; Ganju L
    Appl Microbiol Biotechnol; 2022 Sep; 106(18):6225-6238. PubMed ID: 35976427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.